Research Center for Behavioral Disorders and Substances Abuse, Hamadan University of Medical Sciences, Hamadan, Iran.
Department of Clinical Pharmacy, School of Pharmacy, Hamadan University of Medical Sciences, Hamadan, 6517838678, Iran.
Mol Biol Rep. 2019 Oct;46(5):5333-5343. doi: 10.1007/s11033-019-04989-z. Epub 2019 Jul 25.
Bipolar disorder (BPD) is a severe and chronic mental disease with high rates of social and functional disability. To explain the emergence and maintenance of BPD, increasing attention has been focused on dimensions of inflammation and oxidative stress (OTS). Coenzyme Q10 (CoQ10) is known for its anti-oxidant and anti-inflammatory effects; accordingly, the aim of the present study was to investigate, if compared to placebo, adjuvant CoQ10 might favorably impact on serum levels of inflammatory and OTS biomarkers in patients with BPD during their depressive phase. A total of 89 BPD patients, currently in a depressive episode were allocated by block randomization either to the adjuvant CoQ10 (200 mg/day) condition or to the placebo condition. At baseline and 8 weeks later at the end of the study, serum levels of total antioxidant capacity (TAC), total thiol groups (TTG), catalase activity (CAT), nitric oxide (NO), malondialdehyde (MDA), tumor necrosis factor-alpha (TNF-α), interlukin-6 (IL-6), and IL-10 were assessed. 69 patients completed the 8-week lasting study. Compared to baseline and to the placebo condition, serum levels of TTG and TAC significantly increased, and TNF-α, IL-10, and NO statistically decreased over time in the adjuvant CoQ10 condition. No statistically significant changes were observed for CAT, MDA, and IL-6. The pattern of results suggests that compared to placebo and over a time lapse of 8 weeks, adjuvant CoQ10 favorably impacted on OTS and inflammatory biomarkers in patients with BPD during the depressive episode. Thus, CoQ10 might be considered a safe and effective strategy for treatment of patients with BPD during their depressive phase.
双相障碍 (BPD) 是一种严重且慢性的精神疾病，具有较高的社会和功能残疾率。为了解释 BPD 的发生和维持，越来越多的注意力集中在炎症和氧化应激 (OTS) 维度上。辅酶 Q10 (CoQ10) 以其抗氧化和抗炎作用而闻名；因此，本研究旨在探讨与安慰剂相比，辅助 CoQ10 是否会对 BPD 患者在抑郁期的血清炎症和 OTS 生物标志物水平产生有利影响。共有 89 名目前处于抑郁发作期的 BPD 患者被随机分为辅助 CoQ10（200mg/天）组或安慰剂组。在基线和研究结束时的 8 周后，评估了血清总抗氧化能力 (TAC)、总巯基基团 (TTG)、过氧化氢酶活性 (CAT)、一氧化氮 (NO)、丙二醛 (MDA)、肿瘤坏死因子-α (TNF-α)、白细胞介素-6 (IL-6) 和白细胞介素-10 (IL-10) 的水平。69 名患者完成了为期 8 周的研究。与基线和安慰剂组相比，辅助 CoQ10 组的 TTG 和 TAC 水平显著升高，TNF-α、IL-10 和 NO 水平随时间呈统计学下降。CAT、MDA 和 IL-6 没有观察到统计学上的显著变化。结果表明，与安慰剂相比，在 8 周的时间内，辅助 CoQ10 对 BPD 患者抑郁发作期间的 OTS 和炎症生物标志物产生了有利影响。因此，CoQ10 可能被认为是 BPD 患者在抑郁期的一种安全有效的治疗策略。
